Natus Medical Incorporated
Natus Medical Incorporated NTUS Peers
See (NTUS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NTUS | $32.96 | N/A | 0 | 86.74 | $0.38 | N/A |
| ABT | $133.57 | +0.54% | 232.4B | 17.32 | $7.71 | +1.70% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $105.15 | +0.63% | 155.6B | 76.75 | $1.37 | N/A |
| SYK | $382.48 | +0.03% | 146.2B | 51.27 | $7.46 | +0.86% |
| MDT | $82.94 | +0.64% | 106.4B | 22.66 | $3.66 | +3.37% |
| EW | $78.16 | +0.55% | 45.8B | 32.03 | $2.44 | N/A |
| DXCM | $85.80 | +1.11% | 33.6B | 66.00 | $1.30 | N/A |
| STE | $245.09 | +0.04% | 24.1B | 39.85 | $6.15 | +0.91% |
| PODD | $324.98 | +0.35% | 22.9B | 58.34 | $5.57 | N/A |
Stock Comparison
NTUS vs ABT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ABT has a market cap of 232.4B. Regarding current trading prices, NTUS is priced at $32.96, while ABT trades at $133.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ABT's P/E ratio is 17.32. In terms of profitability, NTUS's ROE is +0.03%, compared to ABT's ROE of +0.31%. Regarding short-term risk, NTUS is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BSX-PA Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NTUS is priced at $32.96, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NTUS's ROE is +0.03%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, NTUS is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BSX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BSX has a market cap of 155.6B. Regarding current trading prices, NTUS is priced at $32.96, while BSX trades at $105.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BSX's P/E ratio is 76.75. In terms of profitability, NTUS's ROE is +0.03%, compared to BSX's ROE of +0.10%. Regarding short-term risk, NTUS is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SYK Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SYK has a market cap of 146.2B. Regarding current trading prices, NTUS is priced at $32.96, while SYK trades at $382.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SYK's P/E ratio is 51.27. In terms of profitability, NTUS's ROE is +0.03%, compared to SYK's ROE of +0.11%. Regarding short-term risk, NTUS is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs MDT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, MDT has a market cap of 106.4B. Regarding current trading prices, NTUS is priced at $32.96, while MDT trades at $82.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas MDT's P/E ratio is 22.66. In terms of profitability, NTUS's ROE is +0.03%, compared to MDT's ROE of +0.09%. Regarding short-term risk, NTUS is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs EW Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, EW has a market cap of 45.8B. Regarding current trading prices, NTUS is priced at $32.96, while EW trades at $78.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas EW's P/E ratio is 32.03. In terms of profitability, NTUS's ROE is +0.03%, compared to EW's ROE of +0.49%. Regarding short-term risk, NTUS is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs DXCM Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, DXCM has a market cap of 33.6B. Regarding current trading prices, NTUS is priced at $32.96, while DXCM trades at $85.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas DXCM's P/E ratio is 66.00. In terms of profitability, NTUS's ROE is +0.03%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, NTUS is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs STE Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, STE has a market cap of 24.1B. Regarding current trading prices, NTUS is priced at $32.96, while STE trades at $245.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas STE's P/E ratio is 39.85. In terms of profitability, NTUS's ROE is +0.03%, compared to STE's ROE of +0.09%. Regarding short-term risk, NTUS is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs PODD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, PODD has a market cap of 22.9B. Regarding current trading prices, NTUS is priced at $32.96, while PODD trades at $324.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas PODD's P/E ratio is 58.34. In terms of profitability, NTUS's ROE is +0.03%, compared to PODD's ROE of +0.35%. Regarding short-term risk, NTUS is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs PHG Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, PHG has a market cap of 21.3B. Regarding current trading prices, NTUS is priced at $32.96, while PHG trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas PHG's P/E ratio is 76.80. In terms of profitability, NTUS's ROE is +0.03%, compared to PHG's ROE of +0.03%. Regarding short-term risk, NTUS is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ZBH Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ZBH has a market cap of 18.2B. Regarding current trading prices, NTUS is priced at $32.96, while ZBH trades at $92.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ZBH's P/E ratio is 20.25. In terms of profitability, NTUS's ROE is +0.03%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, NTUS is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ABMD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NTUS is priced at $32.96, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NTUS's ROE is +0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NTUS is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs ALGN Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ALGN has a market cap of 13.1B. Regarding current trading prices, NTUS is priced at $32.96, while ALGN trades at $180.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ALGN's P/E ratio is 32.96. In terms of profitability, NTUS's ROE is +0.03%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NTUS is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SNN Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, NTUS is priced at $32.96, while SNN trades at $28.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SNN's P/E ratio is 30.80. In terms of profitability, NTUS's ROE is +0.03%, compared to SNN's ROE of +0.08%. Regarding short-term risk, NTUS is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SWAV Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NTUS is priced at $32.96, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NTUS's ROE is +0.03%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, NTUS is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs PEN Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, PEN has a market cap of 10.3B. Regarding current trading prices, NTUS is priced at $32.96, while PEN trades at $267.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas PEN's P/E ratio is 247.33. In terms of profitability, NTUS's ROE is +0.03%, compared to PEN's ROE of +0.04%. Regarding short-term risk, NTUS is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs GMED Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, GMED has a market cap of 8B. Regarding current trading prices, NTUS is priced at $32.96, while GMED trades at $59.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas GMED's P/E ratio is 44.53. In terms of profitability, NTUS's ROE is +0.03%, compared to GMED's ROE of +0.05%. Regarding short-term risk, NTUS is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BIO-B Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BIO-B has a market cap of 6.7B. Regarding current trading prices, NTUS is priced at $32.96, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, NTUS's ROE is +0.03%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, NTUS is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs BIO Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BIO has a market cap of 6.2B. Regarding current trading prices, NTUS is priced at $32.96, while BIO trades at $226.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BIO's P/E ratio is -2.96. In terms of profitability, NTUS's ROE is +0.03%, compared to BIO's ROE of -0.32%. Regarding short-term risk, NTUS is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BRKR Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BRKR has a market cap of 5.6B. Regarding current trading prices, NTUS is priced at $32.96, while BRKR trades at $36.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BRKR's P/E ratio is 70.58. In terms of profitability, NTUS's ROE is +0.03%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, NTUS is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs GKOS Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, NTUS is priced at $32.96, while GKOS trades at $94.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas GKOS's P/E ratio is -41.54. In terms of profitability, NTUS's ROE is +0.03%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, NTUS is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs NARI Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NTUS is priced at $32.96, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas NARI's P/E ratio is -59.24. In terms of profitability, NTUS's ROE is +0.03%, compared to NARI's ROE of -0.18%. Regarding short-term risk, NTUS is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs IRTC Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, IRTC has a market cap of 4.5B. Regarding current trading prices, NTUS is priced at $32.96, while IRTC trades at $140.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas IRTC's P/E ratio is -44.75. In terms of profitability, NTUS's ROE is +0.03%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, NTUS is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs TMDX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, TMDX has a market cap of 4.3B. Regarding current trading prices, NTUS is priced at $32.96, while TMDX trades at $127.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas TMDX's P/E ratio is 90.72. In terms of profitability, NTUS's ROE is +0.03%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, NTUS is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ITGR Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ITGR has a market cap of 4.1B. Regarding current trading prices, NTUS is priced at $32.96, while ITGR trades at $118.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ITGR's P/E ratio is 56.27. In terms of profitability, NTUS's ROE is +0.03%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, NTUS is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs INSP Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, INSP has a market cap of 4.1B. Regarding current trading prices, NTUS is priced at $32.96, while INSP trades at $138.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas INSP's P/E ratio is 63.14. In terms of profitability, NTUS's ROE is +0.03%, compared to INSP's ROE of +0.10%. Regarding short-term risk, NTUS is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs AXNX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NTUS is priced at $32.96, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NTUS's ROE is +0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NTUS is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs PRCT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, NTUS is priced at $32.96, while PRCT trades at $58.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas PRCT's P/E ratio is -34.32. In terms of profitability, NTUS's ROE is +0.03%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NTUS is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs LIVN Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, LIVN has a market cap of 2.4B. Regarding current trading prices, NTUS is priced at $32.96, while LIVN trades at $43.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas LIVN's P/E ratio is -10.63. In terms of profitability, NTUS's ROE is +0.03%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, NTUS is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs NUVA Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NTUS is priced at $32.96, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NTUS's ROE is +0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NTUS is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ATEC Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ATEC has a market cap of 1.8B. Regarding current trading prices, NTUS is priced at $32.96, while ATEC trades at $12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ATEC's P/E ratio is -10.88. In terms of profitability, NTUS's ROE is +0.03%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, NTUS is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs UFPT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, NTUS is priced at $32.96, while UFPT trades at $234.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas UFPT's P/E ratio is 28.74. In terms of profitability, NTUS's ROE is +0.03%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, NTUS is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CNMD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CNMD has a market cap of 1.8B. Regarding current trading prices, NTUS is priced at $32.96, while CNMD trades at $56.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CNMD's P/E ratio is 14.87. In terms of profitability, NTUS's ROE is +0.03%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, NTUS is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs TNDM Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, NTUS is priced at $32.96, while TNDM trades at $19.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas TNDM's P/E ratio is -7.10. In terms of profitability, NTUS's ROE is +0.03%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, NTUS is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs HSKA Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NTUS is priced at $32.96, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NTUS's ROE is +0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NTUS is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs AORT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, NTUS is priced at $32.96, while AORT trades at $29.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas AORT's P/E ratio is -58.04. In terms of profitability, NTUS's ROE is +0.03%, compared to AORT's ROE of -0.07%. Regarding short-term risk, NTUS is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SSII Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SSII has a market cap of 1.2B. Regarding current trading prices, NTUS is priced at $32.96, while SSII trades at $6.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SSII's P/E ratio is -70.33. In terms of profitability, NTUS's ROE is +0.03%, compared to SSII's ROE of -1.33%. Regarding short-term risk, NTUS is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs AHCO Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, NTUS is priced at $32.96, while AHCO trades at $8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas AHCO's P/E ratio is 15.48. In terms of profitability, NTUS's ROE is +0.03%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, NTUS is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SILK Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NTUS is priced at $32.96, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SILK's P/E ratio is -18.96. In terms of profitability, NTUS's ROE is +0.03%, compared to SILK's ROE of -0.29%. Regarding short-term risk, NTUS is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs FNA Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NTUS is priced at $32.96, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas FNA's P/E ratio is -19.83. In terms of profitability, NTUS's ROE is +0.03%, compared to FNA's ROE of -0.36%. Regarding short-term risk, NTUS is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs INMD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, INMD has a market cap of 1B. Regarding current trading prices, NTUS is priced at $32.96, while INMD trades at $14.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas INMD's P/E ratio is 6.57. In terms of profitability, NTUS's ROE is +0.03%, compared to INMD's ROE of +0.25%. Regarding short-term risk, NTUS is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ESTA Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ESTA has a market cap of 994.7M. Regarding current trading prices, NTUS is priced at $32.96, while ESTA trades at $34.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ESTA's P/E ratio is -11.03. In terms of profitability, NTUS's ROE is +0.03%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, NTUS is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs IART Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, IART has a market cap of 983.4M. Regarding current trading prices, NTUS is priced at $32.96, while IART trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas IART's P/E ratio is -33.30. In terms of profitability, NTUS's ROE is +0.03%, compared to IART's ROE of -0.03%. Regarding short-term risk, NTUS is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CSII Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NTUS is priced at $32.96, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CSII's P/E ratio is -20.83. In terms of profitability, NTUS's ROE is +0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NTUS is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs SIBN Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SIBN has a market cap of 805M. Regarding current trading prices, NTUS is priced at $32.96, while SIBN trades at $18.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SIBN's P/E ratio is -29.98. In terms of profitability, NTUS's ROE is +0.03%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, NTUS is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs IRMD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, IRMD has a market cap of 736.6M. Regarding current trading prices, NTUS is priced at $32.96, while IRMD trades at $57.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas IRMD's P/E ratio is 37.37. In terms of profitability, NTUS's ROE is +0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, NTUS is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CRY Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, NTUS is priced at $32.96, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CRY's P/E ratio is 425.71. In terms of profitability, NTUS's ROE is +0.03%, compared to CRY's ROE of -0.07%. Regarding short-term risk, NTUS is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs RXST Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, RXST has a market cap of 621.3M. Regarding current trading prices, NTUS is priced at $32.96, while RXST trades at $15.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas RXST's P/E ratio is -22.82. In terms of profitability, NTUS's ROE is +0.03%, compared to RXST's ROE of -0.10%. Regarding short-term risk, NTUS is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CBLL Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CBLL has a market cap of 607.6M. Regarding current trading prices, NTUS is priced at $32.96, while CBLL trades at $16.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CBLL's P/E ratio is -13.45. In terms of profitability, NTUS's ROE is +0.03%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, NTUS is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BFLY-WT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BFLY-WT has a market cap of 597.3M. Regarding current trading prices, NTUS is priced at $32.96, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, NTUS's ROE is +0.03%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, NTUS is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BFLY Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BFLY has a market cap of 593.5M. Regarding current trading prices, NTUS is priced at $32.96, while BFLY trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BFLY's P/E ratio is -8.00. In terms of profitability, NTUS's ROE is +0.03%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, NTUS is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs AVNS Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, AVNS has a market cap of 581.1M. Regarding current trading prices, NTUS is priced at $32.96, while AVNS trades at $12.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas AVNS's P/E ratio is -1.49. In terms of profitability, NTUS's ROE is +0.03%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, NTUS is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs APEN Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NTUS is priced at $32.96, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas APEN's P/E ratio is -9.43. In terms of profitability, NTUS's ROE is +0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NTUS is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs AXGN Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, AXGN has a market cap of 496M. Regarding current trading prices, NTUS is priced at $32.96, while AXGN trades at $10.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas AXGN's P/E ratio is -68.06. In terms of profitability, NTUS's ROE is +0.03%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, NTUS is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs KIDS Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, KIDS has a market cap of 494.4M. Regarding current trading prices, NTUS is priced at $32.96, while KIDS trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas KIDS's P/E ratio is -11.34. In terms of profitability, NTUS's ROE is +0.03%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NTUS is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SMLR Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SMLR has a market cap of 446.1M. Regarding current trading prices, NTUS is priced at $32.96, while SMLR trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SMLR's P/E ratio is -16.74. In terms of profitability, NTUS's ROE is +0.03%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, NTUS is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs OFIX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, OFIX has a market cap of 440.8M. Regarding current trading prices, NTUS is priced at $32.96, while OFIX trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas OFIX's P/E ratio is -3.04. In terms of profitability, NTUS's ROE is +0.03%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, NTUS is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs NPCE Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, NPCE has a market cap of 433.6M. Regarding current trading prices, NTUS is priced at $32.96, while NPCE trades at $13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas NPCE's P/E ratio is -16.12. In terms of profitability, NTUS's ROE is +0.03%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, NTUS is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BVS Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BVS has a market cap of 430M. Regarding current trading prices, NTUS is priced at $32.96, while BVS trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BVS's P/E ratio is -13.50. In terms of profitability, NTUS's ROE is +0.03%, compared to BVS's ROE of -0.21%. Regarding short-term risk, NTUS is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SRDX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SRDX has a market cap of 415M. Regarding current trading prices, NTUS is priced at $32.96, while SRDX trades at $29.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SRDX's P/E ratio is -20.73. In terms of profitability, NTUS's ROE is +0.03%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, NTUS is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SENS Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SENS has a market cap of 395.4M. Regarding current trading prices, NTUS is priced at $32.96, while SENS trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SENS's P/E ratio is -4.77. In terms of profitability, NTUS's ROE is +0.03%, compared to SENS's ROE of -7.46%. Regarding short-term risk, NTUS is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs TMCI Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, TMCI has a market cap of 361.1M. Regarding current trading prices, NTUS is priced at $32.96, while TMCI trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas TMCI's P/E ratio is -6.75. In terms of profitability, NTUS's ROE is +0.03%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, NTUS is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CTKB Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CTKB has a market cap of 352.1M. Regarding current trading prices, NTUS is priced at $32.96, while CTKB trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CTKB's P/E ratio is -30.89. In terms of profitability, NTUS's ROE is +0.03%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, NTUS is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CLPT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CLPT has a market cap of 333.8M. Regarding current trading prices, NTUS is priced at $32.96, while CLPT trades at $11.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CLPT's P/E ratio is -15.54. In terms of profitability, NTUS's ROE is +0.03%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, NTUS is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs NNOX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, NNOX has a market cap of 326.8M. Regarding current trading prices, NTUS is priced at $32.96, while NNOX trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas NNOX's P/E ratio is -5.63. In terms of profitability, NTUS's ROE is +0.03%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, NTUS is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs VREX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, VREX has a market cap of 318.3M. Regarding current trading prices, NTUS is priced at $32.96, while VREX trades at $7.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas VREX's P/E ratio is -7.45. In terms of profitability, NTUS's ROE is +0.03%, compared to VREX's ROE of -0.08%. Regarding short-term risk, NTUS is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs OM Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, OM has a market cap of 312.6M. Regarding current trading prices, NTUS is priced at $32.96, while OM trades at $17.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas OM's P/E ratio is -0.68. In terms of profitability, NTUS's ROE is +0.03%, compared to OM's ROE of -1.45%. Regarding short-term risk, NTUS is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs PACB Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, PACB has a market cap of 290.8M. Regarding current trading prices, NTUS is priced at $32.96, while PACB trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas PACB's P/E ratio is -0.35. In terms of profitability, NTUS's ROE is +0.03%, compared to PACB's ROE of -1.70%. Regarding short-term risk, NTUS is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs VMD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, VMD has a market cap of 262.8M. Regarding current trading prices, NTUS is priced at $32.96, while VMD trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas VMD's P/E ratio is 22.17. In terms of profitability, NTUS's ROE is +0.03%, compared to VMD's ROE of +0.10%. Regarding short-term risk, NTUS is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ZIMV Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ZIMV has a market cap of 255.2M. Regarding current trading prices, NTUS is priced at $32.96, while ZIMV trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ZIMV's P/E ratio is -10.16. In terms of profitability, NTUS's ROE is +0.03%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, NTUS is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs MXCT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, MXCT has a market cap of 253M. Regarding current trading prices, NTUS is priced at $32.96, while MXCT trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas MXCT's P/E ratio is -5.95. In terms of profitability, NTUS's ROE is +0.03%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, NTUS is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CERS Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CERS has a market cap of 242.8M. Regarding current trading prices, NTUS is priced at $32.96, while CERS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CERS's P/E ratio is -12.70. In terms of profitability, NTUS's ROE is +0.03%, compared to CERS's ROE of -0.35%. Regarding short-term risk, NTUS is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs TCMD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, TCMD has a market cap of 229.7M. Regarding current trading prices, NTUS is priced at $32.96, while TCMD trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas TCMD's P/E ratio is 14.97. In terms of profitability, NTUS's ROE is +0.03%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, NTUS is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SNWV Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SNWV has a market cap of 224.2M. Regarding current trading prices, NTUS is priced at $32.96, while SNWV trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SNWV's P/E ratio is -4.12. In terms of profitability, NTUS's ROE is +0.03%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, NTUS is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs NVRO Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NTUS is priced at $32.96, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NTUS's ROE is +0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NTUS is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for NTUS.
NTUS vs EYES Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, EYES has a market cap of 210M. Regarding current trading prices, NTUS is priced at $32.96, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas EYES's P/E ratio is N/A. In terms of profitability, NTUS's ROE is +0.03%, compared to EYES's ROE of -0.26%. Regarding short-term risk, NTUS is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs MASS Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, MASS has a market cap of 203.3M. Regarding current trading prices, NTUS is priced at $32.96, while MASS trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas MASS's P/E ratio is -2.55. In terms of profitability, NTUS's ROE is +0.03%, compared to MASS's ROE of -0.13%. Regarding short-term risk, NTUS is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs QTRX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, QTRX has a market cap of 201.9M. Regarding current trading prices, NTUS is priced at $32.96, while QTRX trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas QTRX's P/E ratio is -4.19. In terms of profitability, NTUS's ROE is +0.03%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, NTUS is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs TLSI Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, TLSI has a market cap of 193.4M. Regarding current trading prices, NTUS is priced at $32.96, while TLSI trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas TLSI's P/E ratio is -4.65. In terms of profitability, NTUS's ROE is +0.03%, compared to TLSI's ROE of +1.07%. Regarding short-term risk, NTUS is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BWAY Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BWAY has a market cap of 192.6M. Regarding current trading prices, NTUS is priced at $32.96, while BWAY trades at $10.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BWAY's P/E ratio is 46.36. In terms of profitability, NTUS's ROE is +0.03%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, NTUS is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs SGHT Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, SGHT has a market cap of 191.3M. Regarding current trading prices, NTUS is priced at $32.96, while SGHT trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas SGHT's P/E ratio is -3.85. In terms of profitability, NTUS's ROE is +0.03%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, NTUS is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CATX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CATX has a market cap of 190.8M. Regarding current trading prices, NTUS is priced at $32.96, while CATX trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CATX's P/E ratio is -2.09. In terms of profitability, NTUS's ROE is +0.03%, compared to CATX's ROE of -0.27%. Regarding short-term risk, NTUS is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs CVRX Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, CVRX has a market cap of 173M. Regarding current trading prices, NTUS is priced at $32.96, while CVRX trades at $6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas CVRX's P/E ratio is -3.10. In terms of profitability, NTUS's ROE is +0.03%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, NTUS is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs INGN Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, INGN has a market cap of 172.9M. Regarding current trading prices, NTUS is priced at $32.96, while INGN trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas INGN's P/E ratio is -5.59. In terms of profitability, NTUS's ROE is +0.03%, compared to INGN's ROE of -0.15%. Regarding short-term risk, NTUS is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ELMD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ELMD has a market cap of 170.3M. Regarding current trading prices, NTUS is priced at $32.96, while ELMD trades at $20.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ELMD's P/E ratio is 25.71. In terms of profitability, NTUS's ROE is +0.03%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, NTUS is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs LNSR Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, LNSR has a market cap of 161.1M. Regarding current trading prices, NTUS is priced at $32.96, while LNSR trades at $13.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas LNSR's P/E ratio is -2.78. In terms of profitability, NTUS's ROE is +0.03%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, NTUS is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ANIK Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ANIK has a market cap of 160.5M. Regarding current trading prices, NTUS is priced at $32.96, while ANIK trades at $11.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ANIK's P/E ratio is -14.92. In terms of profitability, NTUS's ROE is +0.03%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, NTUS is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs PROF Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, PROF has a market cap of 157.8M. Regarding current trading prices, NTUS is priced at $32.96, while PROF trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas PROF's P/E ratio is -4.27. In terms of profitability, NTUS's ROE is +0.03%, compared to PROF's ROE of -0.70%. Regarding short-term risk, NTUS is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BSGM Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BSGM has a market cap of 152.8M. Regarding current trading prices, NTUS is priced at $32.96, while BSGM trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BSGM's P/E ratio is -10.57. In terms of profitability, NTUS's ROE is +0.03%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, NTUS is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs AVR Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, AVR has a market cap of 152.4M. Regarding current trading prices, NTUS is priced at $32.96, while AVR trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas AVR's P/E ratio is -2.17. In terms of profitability, NTUS's ROE is +0.03%, compared to AVR's ROE of -2.92%. Regarding short-term risk, NTUS is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs LUCD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, LUCD has a market cap of 150.4M. Regarding current trading prices, NTUS is priced at $32.96, while LUCD trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas LUCD's P/E ratio is -1.19. In terms of profitability, NTUS's ROE is +0.03%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, NTUS is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs RCEL Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, RCEL has a market cap of 148.3M. Regarding current trading prices, NTUS is priced at $32.96, while RCEL trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas RCEL's P/E ratio is -2.56. In terms of profitability, NTUS's ROE is +0.03%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, NTUS is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs RPID Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, RPID has a market cap of 146M. Regarding current trading prices, NTUS is priced at $32.96, while RPID trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas RPID's P/E ratio is -3.14. In terms of profitability, NTUS's ROE is +0.03%, compared to RPID's ROE of -0.56%. Regarding short-term risk, NTUS is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs BDMD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, BDMD has a market cap of 137.6M. Regarding current trading prices, NTUS is priced at $32.96, while BDMD trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas BDMD's P/E ratio is 7.86. In terms of profitability, NTUS's ROE is +0.03%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, NTUS is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs LUNG Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, LUNG has a market cap of 136.9M. Regarding current trading prices, NTUS is priced at $32.96, while LUNG trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas LUNG's P/E ratio is -2.18. In terms of profitability, NTUS's ROE is +0.03%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, NTUS is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs MYO Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, MYO has a market cap of 107.2M. Regarding current trading prices, NTUS is priced at $32.96, while MYO trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas MYO's P/E ratio is -21.29. In terms of profitability, NTUS's ROE is +0.03%, compared to MYO's ROE of -0.36%. Regarding short-term risk, NTUS is less volatile compared to MYO. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ICAD Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ICAD has a market cap of 105.2M. Regarding current trading prices, NTUS is priced at $32.96, while ICAD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ICAD's P/E ratio is -20.16. In terms of profitability, NTUS's ROE is +0.03%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, NTUS is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs HJLI Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NTUS is priced at $32.96, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas HJLI's P/E ratio is N/A. In terms of profitability, NTUS's ROE is +0.03%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, NTUS is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.
NTUS vs ASXC Comparison
NTUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTUS stands at 0. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, NTUS is priced at $32.96, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTUS currently has a P/E ratio of 86.74, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NTUS's ROE is +0.03%, compared to ASXC's ROE of -5.59%. Regarding short-term risk, NTUS is less volatile compared to ASXC. This indicates potentially lower risk in terms of short-term price fluctuations for NTUS.